Collateral Therapeutics

Collateral Therapeutics, Inc. of San Diego is a leader in the discovery, development and commercialization of innovative non-surgical gene therapy products for the treatment of cardiovascular diseases. Collateral Therapeutics is developing non-surgical cardiovascular gene therapy products focused on: (1) angiogenesis, as a treatment approach for coronary artery disease, peripheral vascular disease and congestive heart failure; (2) myocardial adrenergic signaling, as a treatment for congestive heart failure; and (3) heart muscle regeneration, to improve cardiac function for patients who have suffered a heart attack. In May 1996, Collateral Therapeutics entered into a strategic alliance with Schering AG, Germany, to develop and commercialize products based on the Company's angiogenesis gene therapy technology. In May 1998, Collateral Therapeutics, together with its strategic partner, Schering AG, began a Phase 1/2 clinical trial for the Company's lead product GENERX(TM), a non-surgical angiogenic gene therapy product for the treatment of patients with stable exertional angina which is being conducted at ten major U.S. medical centers.

Previous Forums
Date/Time		Forum
Nov 15 2000		BIO-Europe 2000
May 20 2000		Biospace.com San Diego Biotech Beach 2000 Stocks Forum
Jan 15 2000		BioSpace.com Bay Area Biotechnology Stocks Forum
Nov 20 1999		Second Bay Area Drug Delivery Stocks Forum
Mar 13 1999		Fourth San Diego Biotech Stocks Forum
Mar 4 1999		Atlanta Health Care Stocks Forum
Feb 13 1999		Surgical Advances Stocks Forum
Jan 23 1999		Second Beltway Biotechnology Stocks Forum - Bethsda, MD

Market Assistant		PrecisionAlert
This company has no data		Enter your email address to receive alerts about this company